Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.
G KerdivelV ChesnaisE BechtA TomaN CagnardF DumontA RousseauP FenauxS ChevretN ChapuisV BoevaW H FridmanMichaela FontenayO KosmiderPublished in: Leukemia (2017)